- TechForce Robotics has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics, marking the company’s first operational entry into pharmaceutical and laboratory automation.
- The deployment fulfills Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows.
- A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications.
Laboratory and pharmaceutical operations increasingly face the same challenge that has accelerated automation across industries from manufacturing to hospitality: how to improve efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.
TechForce Robotics, Inc. (“TechForce”), the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), is positioning itself to address that opportunity by extending its Robotics-as-a-Service (“RaaS”) platform into pharmaceutical and laboratory automation.
Extending an Established Automation Platform
TechForce has built its platform around autonomous mobile systems designed to improve operational efficiency across commercial environments. Much of its initial focus centered on hospitality and service-industry applications, where robots transport linens, waste, supplies, and other materials throughout facilities while reducing repetitive manual tasks. The company’s latest deployment shows how that same underlying technology may be adapted for an entirely different operating environment.
In June, TechForce announced the completion of Phase 1 objectives under a joint development agreement with Oncotelic Therapeutics, Inc. (OTCQB: OTLC) through the initial deployment of LIM-E, an autonomous laboratory support robot built to assist with approved laboratory logistics workflows. The deployment marks TechForce’s first operational expansion into pharmaceutical automation and demonstrates the platform’s flexibility across industry verticals. Rather than moving hospitality materials, LIM-E is configured to transport approved laboratory supplies and properly contained materials within designated laboratory environments. The application differs from hospitality settings, but the underlying objective remains the same: improving workflow efficiency through autonomous logistics support.
The Significance of the Oncotelic Collaboration
The deployment is part of a broader collaboration aimed at evaluating how robotics and AI-enhanced automation may support future pharmaceutical manufacturing and laboratory operations. The agreement extends beyond a single deployment. The framework is intended to generate operational data, workflow observations, and performance feedback that can inform future automation initiatives within regulated pharmaceutical environments. Future areas of evaluation may include laboratory logistics, manufacturing support processes, AI-enhanced workflows, and other initiatives designed to improve consistency, efficiency, and scalability.
For organizations operating under Good Manufacturing Practice (“GMP”) requirements, even incremental workflow improvements can produce meaningful benefits. Automation that handles repetitive support functions may allow scientific personnel to dedicate more time to research, development, quality control, and manufacturing.
Why Robotics-as-a-Service Matters
One of the more notable aspects of TechForce’s strategy is its reliance on a Robotics-as-a-Service model. Robotics adoption has historically required substantial upfront capital, specialized integration, and ongoing maintenance commitments that can discourage organizations from pursuing automation. The RaaS model seeks to address those barriers by providing access to robotic systems through recurring service arrangements rather than large initial purchases.
For pharmaceutical and biotechnology organizations weighing automation initiatives, that approach may offer greater flexibility while reducing implementation risk. Companies can potentially deploy systems without significant capital commitments, while providers such as TechForce retain responsibility for support, updates, and optimization. Management believes the model can be applied across multiple industries using a common technology foundation, opening new vertical markets without requiring entirely separate robotics platforms.
Building a Multi-Industry Growth Strategy
The company’s expansion into pharmaceutical automation is also supported by efforts to strengthen its underlying engineering and manufacturing capabilities. This week, TechForce announced a strategic supply and development agreement with Taiwan-based JJ Enterprise, a precision engineering and advanced manufacturing company serving the semiconductor, automation, and specialty materials industries. Management believes the relationship will provide access to expertise in areas such as precision automation, machine vision, advanced materials processing, and semiconductor-grade manufacturing disciplines that are increasingly relevant to laboratory and pharmaceutical environments. The collaboration is expected to support future development initiatives across pharmaceutical automation, laboratory robotics, intelligent manufacturing systems, and other high-precision applications.
The pharmaceutical deployment arrives amid broader efforts to expand TechForce’s automation ecosystem and establish the engineering infrastructure needed to support increasingly sophisticated automation projects. Recent initiatives include the launch of an Enterprise Automation Division aimed at larger-scale projects and a strategic partnership with deployment provider ToDo Robotics, which has completed more than 300 robotic system deployments nationwide. Together, those moves reflect a strategy built around a diversified automation platform serving multiple sectors through robotics hardware, AI-enhanced software, deployment expertise, and recurring service relationships.
As automation adoption expands across healthcare, life sciences, logistics, and hospitality, TechForce’s pharmaceutical deployment offers an early example of how robotics platforms developed for one industry can be adapted to serve another. Combined with the company’s strategic alliance with JJ Enterprise to support advanced manufacturing and precision automation initiatives, the LIM-E deployment represents another step in TechForce’s efforts to expand its Robotics-as-a-Service platform into new high-value industrial and life sciences markets.
For more information, visit the company’s website at TechForceRobotics.com
NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF
